Showing results (11-20 of 62) with videos related to
Sort By:
Pageof 7
Gynecologic Oncology|February 19, 2011
Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group studyJohn Farley, Michael W Sill, Michael Birrer, et al.Cancer Causes & Control : CCC|October 18, 2012
A modified Latent Class Model assessment of human papillomavirus-based screening tests for cervical lesions in women with atypical glandular cells: a Gynecologic Oncology Group studyRandy L Carter, Le Kang, Kathleen M Darcy, et al.Gynecologic Oncology|July 7, 2015
Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group studyIsrael Zighelboim, Shamshad Ali, Heather A Lankes, et al.Gynecologic Oncology|January 12, 2020
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)Alessandro D Santin, Wei Deng, Michael Frumovitz, et al.JAMA Oncology|November 28, 2019
Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical CancerJyoti S Mayadev, Danielle Enserro, Yvonne G Lin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2010
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trialDaniela Matei, Michael W Sill, Heather A Lankes, et al.The Lancet. Oncology|December 25, 2012
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 studyJohn Farley, William E Brady, Vinod Vathipadiekal, et al.Gynecologic Oncology Reports|September 5, 2020
Corrigendum to "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)" [Gynecol. Oncol. Rep. 31 (2020) 100532]Alessandro D Santin, Virginia Filiaci, Stefania Bellone, et al.Gynecologic Oncology|August 14, 2017
A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group studyPremal H Thaker, William E Brady, Heather A Lankes, et al.Gynecologic Oncology|August 14, 2012
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancerKimberly K Leslie, Michael W Sill, Heather A Lankes, et al.Pageof 7